GLMD - ガルメド・ファ―マシュ―ティカルズ (Galmed Pharmaceuticals Ltd.) ガルメド・ファ―マシュ―ティカルズ

 GLMDのチャート


 GLMDの企業情報

symbol GLMD
会社名 Galmed Pharmaceuticals Ltd. (ガルメド・ファ―マシュ―ティカルズ)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company. The Company focuses on the development and commercialization of once-daily oral therapy for the treatment of liver diseases and cholesterol gallstones utilizing its synthetic fatty-acid/bile-acid conjugate (FABAC) called aramchol. Its product candidate aramchol is a disease modifying treatment for fatty liver disorders including Non-Alcoholic Steato-hepatitis (NASH). The Company''s Aramchol is a conjugate of cholic acid and arachidic acid which is a member of synthetic Fatty-Acid/Bile-Acid Conjugates (FABACs). FABACs are composed of endogenic compounds. Aramchol affects liver fat metabolism and has been shown in a Phase IIa clinical study to reduce liver fat content as well as improve metabolic parameters associated with Nonalcoholic steatohepatitis (NASH). Aramchol is in Phase IIb clinical trials.   ガルメド・ファ―マシュ―ティカルズはイスラエルの臨床段階のバイオ医薬品会社。肝臓疾患やコレステロ―ル胆石のための一日一回経口療法の新治療薬の開発・商品化に従事。画期的医薬品(ファ―スト・イン・クラス)には、脂肪酸と胆汁酸を結合させた「aramchol」があり、非アルコ―ル脂肪性肝炎などの脂肪管疾患の応用治療となる製品候補を保有する。   Galmed Pharmaceuticals Ltd. is a clinical stage drug development biopharmaceutical company for liver, metabolic and inflammatory diseases. Its lead compound, Aramchol™, a backbone drug candidate for the treatment of NASH and fibrosis is currently in a Phase 3 registrational study.It is also collaborating with the Hebrew University in the development of Amilo-5MER, a 5 amino acid synthetic peptide and plan to initiate a first in human study by the first quarter of 2021.
本社所在地 16 Tiomkin Street Tel Aviv 6578317 ISR
代表者氏名 Chaim Hurvitz チャイム・ハービッツ
代表者役職名 Chairman of the Board 取締役会会長
電話番号 +972 3-693-8448
設立年月日 41456
市場名 NASDAQ Small Cap
ipoyear 2014年
従業員数 17人
url www.galmedpharma.com
nasdaq_url https://www.nasdaq.com/symbol/glmd
adr_tso
EBITDA EBITDA(百万ドル) -11.49600
終値(lastsale) 12.32
時価総額(marketcap) 257645129.28
時価総額 時価総額(百万ドル) 241.76590
売上高 売上高(百万ドル) 1.08500
企業価値(EV) 企業価値(EV)(百万ドル) 147.66090
当期純利益 当期純利益(百万ドル) -11.63600
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Galmed Pharmaceuticals Ltd revenues remained flat at $538K. Net loss decreased 11% to $5.2M. Revenues reflect market conditions. Lower net loss reflects Research and development expenses decrease of 24% to $3.9M (expense) Financial expenses net increase of 29% to $143K (income). Basic Earnings per Share excluding Extraordinary Items increased from -$0.48 to -$0.34.

 GLMDのテクニカル分析


 GLMDのニュース

   Galmed Pharmaceuticals Ltd. (GLMD) CEO Allen Baharaff on Q2 2021 Results - Earnings Call Transcript  2021/08/09 15:00:53 Seeking Alpha
   Galmed Pharmaceuticals Ltd Shares Close the Week 22.9% Higher - Weekly Wrap  2021/08/07 16:24:24 Kwhen Finance
Galmed Pharmaceuticals Ltd (GLMD) shares closed this week 22.9% higher than it did at the end of last week. The stock is currently down 1.6% year-to-date, down 33.6% over the past 12 months, and down 26.3% over the past five years. This week, the Dow Jones Industrial Average fell 0.1%, and the S&P 500 rose 0.3%. Trading Activity Shares traded as high as $3.42 and as low as $2.60 this week.Shares closed 51.0% below its 52-week high and 42.3% above its 52-week low.Trading volume this week was 86.9% lower than the 10-day average and 65.4% lower than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.6. Technical Indicators The Relative Strength Index (RSI) on the stock was above 70, indicating it may be overbought.MACD, a trend-following momentum indicator, indicates an upward trend.The stock closed below its Bollinger band, indicating it may be oversold.The stock closed at 6.4% higher than its 5-day moving average, 14.0% higher than its 20-day moving average, and 3.7% higher than its 90-day moving average. Market Comparative Performance The company's share price beats the S&P 500 Index this week, lags it on a 1-year basis, and lags it on a 5-year basis The company's share price beats the Dow Jones Industrial Average this week, lags it on a 1-year basis, and lags it on a 5-year basis The company share price beats the performance of its peers in the Health Care industry sector this week, lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by -90.6% The company's stock price performance over the past 12 months lags the peer average by -1262.5% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.
   Galmed Stock Jumps As FDA Signs Off Use Of Aramchol Meglumine In Late Stage NASH Trial  2021/08/02 13:26:12 Benzinga
The FDA has agreed with Galmed Pharmaceuticals Ltd''s (NASDAQ: GLMD ) plan to use Aramchol meglumine (instead of Aramchol free acid) in its Phase 3 ARMOR study without the need for additional studies other than planned limited Full story available on Benzinga.com
   FDA Agrees with Galmed''s Plan to use Aramchol Meglumine in the Randomized Double-Blind Placebo-Controlled Part of the Phase 3 ARMOR study  2021/08/02 11:30:00 PR Newswire
TEL AVIV, Israel, Aug. 2, 2021 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic and inflammatory diseases announced today that the FDA agreed with its plan to use Aramchol meglumine (in
   Lipodystrophy Pipeline | A Clinical Trials Analysis Report | DelveInsight  2021/06/10 00:00:00 Benzinga
Los Angeles, USA, June 09, 2021 (GLOBE NEWSWIRE) -- Lipodystrophy Pipeline | A Clinical Trials Analysis Report | DelveInsight The companies with their Lipodystrophy drug candidates in the most advanced stage (Phase III stage) include Ionis Pharmaceuticals, soon drifting the Lipodystrophy Pipeline landscape. DelveInsight''s " Lipodystrophy Pipeline Insight " report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in the Lipodystrophy pipeline landscapes. It comprises Lipodystrophy pipeline drug profiles, including clinical and non-clinical stage products. It also includes the Lipodystrophy therapeutics assessment by product type, stage, route of administration, and molecule type and further highlights the inactive Lipodystrophy pipeline products. Some of the key takeaways from the Lipodystrophy Pipeline Report Notable companies such as Regeneron Pharmaceuticals, Ionis Pharmaceuticals, Pfizer, Amunix, Zydus Cadila, Galmed Pharmaceuticals, Cell Praxis, Carmot Therapeutics, CombiGene and others are developing potential drug candidates to boost the Lipodystrophy treatment scenario.
   Lipodystrophy Pipeline | A Clinical Trials Analysis Report | DelveInsight  2021/06/10 00:00:00 Benzinga
Los Angeles, USA, June 09, 2021 (GLOBE NEWSWIRE) -- Lipodystrophy Pipeline | A Clinical Trials Analysis Report | DelveInsight The companies with their Lipodystrophy drug candidates in the most advanced stage (Phase III stage) include Ionis Pharmaceuticals, soon drifting the Lipodystrophy Pipeline landscape. DelveInsight''s " Lipodystrophy Pipeline Insight " report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in the Lipodystrophy pipeline landscapes. It comprises Lipodystrophy pipeline drug profiles, including clinical and non-clinical stage products. It also includes the Lipodystrophy therapeutics assessment by product type, stage, route of administration, and molecule type and further highlights the inactive Lipodystrophy pipeline products. Some of the key takeaways from the Lipodystrophy Pipeline Report Notable companies such as Regeneron Pharmaceuticals, Ionis Pharmaceuticals, Pfizer, Amunix, Zydus Cadila, Galmed Pharmaceuticals, Cell Praxis, Carmot Therapeutics, CombiGene and others are developing potential drug candidates to boost the Lipodystrophy treatment scenario.
   Why Is Penny Stock Galmed Pharma A Strong Buy With Triple-Digit Upside?  2021/06/05 21:06:36 Bitcoin Ethereum News
The post Why Is Penny Stock Galmed Pharma A Strong Buy With Triple-Digit Upside? appeared on BitcoinEthereumNews.com . Galmed Pharmaceuticals (GLMD) is a clinical-stage biopharmaceutical company focused on developing Aramchol, a stearoyl-coenzyme A desaturase1 (SCD1) modulator that targets the liver. Aramchol is a novel oral therapy for the
   Analysts Offer Insights on Healthcare Companies: Jazz Pharmaceuticals (JAZZ), SenesTech (SNES) and Galmed Pharmaceuticals (GLMD)  2021/05/17 10:16:48 Smarter Analyst
Theres a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Jazz Pharmaceuticals (JAZZ), SenesTech (SNES) The post Analysts Offer Insights on Healthcare Companies: Jazz Pharmaceuticals (JAZZ), SenesTech (SNES) and Galmed Pharmaceuticals (GLMD) appeared first on Smarter Analyst .
   Galmed Pharmaceuticals Ltd. (GLMD) CEO Allen Baharaff on Q1 2021 Results - Earnings Call Transcript  2021/05/13 22:58:06 Seeking Alpha
   Analysts Have Conflicting Sentiments on These Healthcare Companies: Galmed Pharmaceuticals (GLMD), ADMA Biologics (ADMA) and Corbus Pharmaceuticals (CRBP)  2021/05/13 20:45:20 Smarter Analyst
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Galmed Pharmaceuticals (GLMD), ADMA Biologics (ADMA) The post Analysts Have Conflicting Sentiments on These Healthcare Companies: Galmed Pharmaceuticals (GLMD), ADMA Biologics (ADMA) and Corbus Pharmaceuticals (CRBP) appeared first on Smarter Analyst .
   Galmed to add Open Label Part to ARMOR Study; First Read-out Expected in Q4 2021  2020/12/17 12:00:00 PR Newswire
TEL AVIV, Israel, Dec. 17, 2020 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic and inflammatory diseases announced today the addition of an open-label part to its ARMOR Phase 3…
   Galmed Pharmaceuticals Reports Third Quarter 2020 Financial Results  2020/11/12 12:00:00 PR Newswire
TEL AVIV, Israel, Nov. 12, 2020 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of the liver targeted SCD1 modulator Aramchol™, an oral therapy for the treatment of nonalcoholic…
   The Daily Biotech Pulse: Lilly's COVID-19 Antibody Treatment Approved For Emergency Use, Supernus Faces Twin Regulatory Setbacks, Revance, Arena Flunk Midstage Studies  2020/11/10 13:40:14 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Nov. 9) Alcon AG (NYSE: ALC ) Aligos Therapeutics Inc (NASDAQ: ALGS ) Aptevo Therapeutics Inc (NASDAQ: APVO ) (announced second complete remission in a patient in Cohort 6 of a Phase 1 study of AVO436 in acute myeloid leukemia and myelodysplastic syndrome patients) Bio-Rad Laboratories, Inc. Class A Common Stock (NYSE: BIO ) BIO-TECHNE Corp (NASDAQ: TECH ) BioLife Solutions Inc (NASDAQ: BLFS ) BioNTech SE – ADR (NASDAQ: BNTX ) - announced over 90% efficacy in the Phase 3 study of its coronavirus vaccine candidate co-developed with Pfizer Inc. (NYSE: PFE ) C4 Therapeutics Inc (NASDAQ: CCCC ) Calliditas Therapeutics Adr Rep 2 Ord Shs (NASDAQ: CALT ) (announced positive topline results from Part A of the Phase 3 clinical trial of Nefecon in patients with primary IgA nephropathy) Catalent Inc (NYSE: CTLT ) Denali Therapeutics Inc (NASDAQ: DNLI ) Fate Therapeutics Inc (NASDAQ: FATE ) Halozyme Therapeutics, Inc.
   Galmed Pharmaceuticals to Report Third Quarter 2020 Financial Results and Provide Business Update on Thursday November 12  2020/11/05 13:30:00 PR Newswire
TEL AVIV, Israel, Nov. 5, 2020 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of Aramchol, a liver targeted, oral, SCD1 modulator, currently in Phase 3 clinical trial for the…
   Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) Given Average Recommendation of “Buy” by Brokerages  2020/10/25 00:28:44 US Banking News
Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) has earned an average rating of “Buy” from the eleven research firms that are presently covering the company, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a hold recommendation and nine have assigned a buy recommendation to the company. The average 1 year target price among analysts […]

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 ガルメド・ファ―マシュ―ティカルズ GLMD Galmed Pharmaceuticals Ltd.)

 twitter  (公式ツイッターやCEOツイッターなど)